Royalty Pharma plc (RPRX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

24/25

Growth 5 Margin 5 Expansion 4 Platform 5 Financial 5

latest quarter score

Earnings Reports

24
Royalty Pharma (RPRX) Q2 2026: Portfolio Receipts Up 6% as Blockbuster Pipeline Expands
August 05, 2026
22
Royalty Pharma (RPRX) Q4 2025: Synthetic Royalties Hit 44% of Deals, Unlocking New Growth Channels
June 15, 2026
22
Royalty Pharma (RPRX) Q1 2026: R&D Co-Funding Surges to $1B, Unlocking New Growth Pathways
May 06, 2026
20
Royalty Pharma (RPRX) Q3 2025: $1.7B Deployed as Synthetic Royalties Expand Pipeline Depth
November 05, 2025
21
Royalty Pharma (RPRX) Q2 2025: Portfolio Receipts Up 20% as Synthetic Royalty Model Scales
August 06, 2025
21
Royalty Pharma (RPRX) Q1 2025: Share Repurchases Hit $723M as Portfolio Receipts Climb 17%
July 07, 2025

Browse all companies